Molecule selection involves the pre-clinical and clinical risk-assessment by pharma and generics companies to determine which molecules are likely to provide a successful route for the development into market by considering the market, cost, risk (competition, technical feasibility, regulatory) and benefit. This is the earliest gate in the NPD process and will decide what will come into the pipeline first.